Every direction of research shows massive growth.
treat this disease like diabetes with injection pump with Sarepta's drug and the benefit with be the best.I am thinking daily doses of 15m and maybe less after 2 weeks
i think those other 5 days decending is why you see a fading walk test after 144 weeks ,even that most of those kid would be in the weel weelchair by now without the treatment.
a steady flow of a drug is smooth ''every day'' 'weekly'' drug dosing is up and down .i am suggesting that under the current treatment by the week it will slow down the disease but dosing every day by a injection pump with the same drug ''it will extend the benefit even more.
After taking this drug every seven days or weekly over say 3 years you have that empty space of time say in between the doses and i believe this could be a factor on progression when using exon skipping ......to correct this, one could do daily dosing that would allow a more even flow of production with a longer benefit time.
and fired that slacker and i am still long on Sarepta because they do still have the only real treatment for DMD available worth anything.I have found another favorite stock long term if anyone is interested/
long term and less taxes for gild.................bullish
you got to be a poor researcher or a short scared as hell
Simple math.........................................................or higher
never seen such scams when it comes to a number one buy.
UNLESS YOU ARE IMPAIRED SOMEHOW..
This is so plain and simple
on many of these good stocks.The government has caused much of this for a tax collecting method .The big boys knew it ahead of time.I also think once a certain goal is reached then it will turn.This stock is way to low by 2 points..
i found a solution for this drug.I am thinking that if you treated dmd with a daily insulin type pump you would get a lessor progression rate than a once weekly dose and it would go much further than 5 years,I really am tired of the one egg in the basket here,
Based on our analysis of domestic product sales trends, likely effects of currency, shipping days, weather and other seasonal effects we are quite positive about the outlook for the approaching earnings season for the biotech stocks in our coverage. It is worth remembering that Q2 is typically the best quarter of the year for biotech companies across the board – Q1 headwinds from co-payments, deductibles and “donut holes”
are over, shipping days usually peak, weather effects are minimal and management teams are inclined to signal more of their full and realistic earnings potential for the year, lest they be accused of “sandbagging” for the year after a decent first half. Clearly the most likely company to surprise to the upside is Gilead…
We increased our forecast for Truvada, Complera, and Stribild, and trimmed our forecast for Viread and Atripla. Our analysis points to US Sovaldi revenue above $3bn, well above recent consensus of $2.6bn; we are also expecting $700mm in OUS revenue for Sovaldi in the quarter. Our total revenue forecast for Q2 is now over $7bn, or 24% above recent consensus. Our EPS estimate is $2.24, or 35% above recent consensus